BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 18571942)

  • 1. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma.
    Raffaghello L; Conte M; De Grandis E; Pistoia V
    Eur J Paediatr Neurol; 2009 May; 13(3):219-23. PubMed ID: 18571942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
    Raffaghello L; Fuhlhuber V; Bianchi G; Conte M; Blaes F; Gambini C; Pistoia V
    J Leukoc Biol; 2013 Jul; 94(1):183-91. PubMed ID: 23610147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies in childhood opsoclonus-myoclonus syndrome.
    Blaes F; Pike MG; Lang B
    J Neuroimmunol; 2008 Sep; 201-202():221-6. PubMed ID: 18687475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New autoantibodies in pediatric opsoclonus myoclonus syndrome.
    Kirsten A; Beck S; Fühlhuber V; Kaps M; Kreutz T; Korfei M; Schmitt S; Preissner KT; Blaes F
    Ann N Y Acad Sci; 2007 Sep; 1110():256-60. PubMed ID: 17911440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS).
    Krasenbrink I; Fühlhuber V; Juhasz-Boess I; Stolz E; Hahn A; Kaps M; Hero B; Blaes F
    Neuropediatrics; 2007 Jun; 38(3):114-6. PubMed ID: 17985258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
    Fühlhuber V; Bick S; Kirsten A; Hahn A; Gerriets T; Tschernatsch M; Kaps M; Preissner KT; Blaes F; Altenkämper S
    J Neuroimmunol; 2009 May; 210(1-2):87-91. PubMed ID: 19339060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome.
    Korfei M; Fühlhuber V; Schmidt-Wöll T; Kaps M; Preissner KT; Blaes F
    J Neuroimmunol; 2005 Dec; 170(1-2):150-7. PubMed ID: 16203043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG subclass distribution of autoantibodies in pediatric opsoclonus-myoclonus syndrome.
    Beck S; Fühlhuber V; Krasenbrink I; Tschernatsch M; Kneifel N; Kirsten A; Jaeger C; Kaps M; Preissner KT; Lang B; Rostasy K; Blaes F
    J Neuroimmunol; 2007 Apr; 185(1-2):145-9. PubMed ID: 17324472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome.
    Zar T; Tschernatsch M; Hero B; Lang B; Preissner KT; Blaes F
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e176-e179. PubMed ID: 33060390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Opsoclonus myoclonus ataxia syndrome in Israel].
    Blumkin L; Lerman-Sagie T
    Harefuah; 2010 Jan; 149(1):24-8, 63. PubMed ID: 20422836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of autoantigens in pediatric opsoclonus-myoclonus syndrome.
    Blaes F; Fühlhuber V; Preissner KT
    Expert Rev Clin Immunol; 2007 Nov; 3(6):975-82. PubMed ID: 20477144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opsoclonus-myoclonus syndrome associated with neuroblastoma: Insights into antitumor immunity.
    Du H; Cai W
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29949. PubMed ID: 36094353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of identical B-cell clone in both cerebrospinal fluid and tumor tissue in a patient with opsoclonus-myoclonus syndrome associated with neuroblastoma.
    Noguchi K; Ikawa Y; Takenaka M; Sakai Y; Fujiki T; Kuroda R; Ikeda H; Nakada S; Nomura K; Sakai S; Fukuda M; Araki R; Takahashi Y; Wada T
    Pediatr Hematol Oncol; 2023 May; 40(4):363-370. PubMed ID: 36125271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.
    Cooper R; Khakoo Y; Matthay KK; Lukens JN; Seeger RC; Stram DO; Gerbing RB; Nakagawa A; Shimada H
    Med Pediatr Oncol; 2001 Jun; 36(6):623-9. PubMed ID: 11344493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma.
    Ding X; Yang W; Ren Q; Hu J; Yang S; Han W; Wang J; Wang X; Wang H
    J Neuroinflammation; 2020 Jun; 17(1):190. PubMed ID: 32546235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma.
    Morales La Madrid A; Rubin CM; Kohrman M; Pytel P; Cohn SL
    Pediatr Blood Cancer; 2012 Mar; 58(3):472-4. PubMed ID: 21480475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on opsoclonus.
    Wong A
    Curr Opin Neurol; 2007 Feb; 20(1):25-31. PubMed ID: 17215685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("Tumor" vs. "No tumor") in a cohort of 356 US children.
    Pranzatelli MR; Tate ED; McGee NR
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27097. PubMed ID: 29727049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment.
    Blaes F; Dharmalingam B
    Expert Rev Neurother; 2016 Jun; 16(6):641-8. PubMed ID: 27095464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Opsoclonus-myoclonus syndrome in children with neuroblastoma: description of 3 cases].
    Garus K; Balwierz W; Skowronek B; Szweda E; Kroczka S; Moryl-Bujakowska A
    Przegl Lek; 2010; 67(6):427-9. PubMed ID: 21344775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.